<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700358</url>
  </required_header>
  <id_info>
    <org_study_id>20-1287_1</org_study_id>
    <nct_id>NCT04700358</nct_id>
  </id_info>
  <brief_title>Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis</brief_title>
  <official_title>Identification and Characterization of Antibacterial Antibodies in Sera of Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria&#xD;
      such as Pseudomonas aeruginosa or Staphylococcus aureus. Aim of this study is to detect&#xD;
      virulence factor neutralizing antibodies in the sera of the study population followed by B&#xD;
      cell repertoire analyses to design B cell-derived neutralizing monoclonal antibodies. The&#xD;
      functionality of neutralizing antibodies rests on inhibition of virulence factors by binding&#xD;
      of crucial epitopes rather than merely the induction of opsonization. Focusing on patients&#xD;
      with bacterial colonization/chronic infections or a history of an acute infection in the&#xD;
      past, will increase the likelihood for identification of serum with neutralizing activity as&#xD;
      in vivo antigen contact is a prerequisite for antibody development and maturation. Since&#xD;
      virulence factors are essential for infection, dissemination and tissue damage, inhibition of&#xD;
      these factors by developed neutralizing antibodies might contribute to a favorable outcome of&#xD;
      life-threatening infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of antibacterial antibodies</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pulmonary Cystic Fibrosis</condition>
  <condition>Neutralizing Antibodies</condition>
  <arm_group>
    <arm_group_label>Patients with Cystic Fibrosis</arm_group_label>
    <description>Patients with pulmonary Cystic Fibrosis with or without bacterial colonization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Screening: Blood sampling of 15 ml whole blood&#xD;
B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patients with Cystic Fibrosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and PBMCs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of the University Hospital Cologne&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
          -  Normal vital signs including:&#xD;
&#xD;
          -  Blood pressure systolic value 150 - 100 mmHg, diastolic value &lt; 90 mmHg&#xD;
&#xD;
          -  Respiratory rate &lt; 20/min&#xD;
&#xD;
          -  Oxygen saturation &gt;92%&#xD;
&#xD;
          -  Heart rate 50 - 110/min&#xD;
&#xD;
          -  Body temperature &lt;38°C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cytopenia (leukocytes &lt; 1.500/µl, thrombocytes &lt; 50.000/µl, Hemoglobin &lt; 12 g/dl)&#xD;
&#xD;
          -  Heart disease or pulmonary hypertension&#xD;
&#xD;
          -  Body weight &lt;50 kg (exclusion of blood sampling for B cell isolation)&#xD;
&#xD;
          -  Blood donation, larger blood loss and/or major surgery in the last 8 (male) or 12&#xD;
             (female) weeks&#xD;
&#xD;
          -  Any decline of the general state of health in the last 3 month including weight loss &gt;&#xD;
             2kg, pulmonal exacerbation or increased impairment of pulmonary function (FEV1 &lt; 50%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Rybniker, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Simonis</last_name>
    <phone>+4922147889608</phone>
    <email>alexander.simonis@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>CF Study Center, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernst Rietschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Rybniker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Simonis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Alexander Simonis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

